Skip to main content

No One Should Die Of Cancer

Over one-third of people in developed countries develop cancer and 8.2 million people die from cancer every year. Angiex is committed to being part of the solution to the problem.

Our latest findings:

Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, participated in the 13th Annual World ADC Meeting in San Diego, California. During the meeting, the company provided an overview of its technology and near-term plans for its lead asset, AGX101, in its poster “AGX101 – A novel TM4SF1-directed ADC for the treatment of all solid tumors.”

Our Science

Angiex’s Nuclear Delivery Platform™ delivers chemotherapeutic payloads to the nucleus of tumor cells and the endothelial cells of tumor blood vessels, offering the potential to create drugs for solid cancers with exceptional efficacy and therapeutic margin.

Angiex’s lead ND-ADC, AGX101, enters the clinic in 2022, and a pipeline of additional ND-ADCs is in discovery-stage development. Angiex founders discovered VEGF-A, have been recognized as the world’s leading experts in tumor blood vessel biology, developed new methods for per cell mRNA quantification, founded four companies, wrote a best-selling diet book, and won second prize for best salsa recipe at LabCentral. Angiex is eager to team up with creative talents to end the scourge of cancer.

Latest Angiex News

Angiex News

Angiex Further Bolsters its Executive Team with the Appointment of Jason Sager, MD, as Chief Medical Officer

Dr. Sager joins after 18 months as part-time CMO, in which he built the clinical…
Angiex News

Angiex submits IND to FDA for AGX101 

CAMBRIDGE, Mass. — September 19, 2022:  Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for…
Angiex News

Angiex Joins the Leaders in the Field of Antibody-Drug Conjugates at 13th Annual World ADC Meeting in San Diego

Company provides background on its technology platform and AGX101, its lead assetCAMBRIDGE, Mass. — September…